Cancer Treatment Market Research Reports & Industry Analysis
Cancer is a disease characterized by uncontrolled cell proliferation. Of the more than 100 types of cancer, lung, breast, and colorectal cancer account for nearly half of new cases per year in the United States. Lung cancer, which is highly correlated with cigarette smoking, is responsible for more deaths than any other form of cancer. Cigarette smoking and other environmental factors are associated with the majority of cancers.
With the growing incidence of cancer, a growing and aging world population and significant medical advances, there will continue to be phenomenal growth in the market for cancer diagnosis and treatment products.
Cancer Treatment Industry Research & Market Reports
-
mRNA Platform
... CAGR of -2.7% over the analysis period 2024-2030. Covid-19 Vaccine, one of the segments analyzed in the report, is expected to record a -6.3% CAGR and reach US$102.1 Billion by the end of the analysis ... Read More
-
Tumor / Cancer Markers
... 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 10.4% CAGR The Tumor / Cancer Markers market ... Read More
-
Liver Cancer Diagnostics
... at a CAGR of 7.4% over the analysis period 2024-2030. Laboratory Tests, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$9.8 Billion by the end of ... Read More
-
Chronic Myelogenous Leukemia Treatment
... 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Disease Specific Treatment, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$3.4 Billion by ... Read More
-
Global MHC-Peptide Tetramer Market Insights, Forecast to 2031
... Tetramer is estimated to increase from 63.45 million USD in 2024 to reach 116.42 million USD by 2031, at a CAGR of 9.80% during the forecast period of 2025 through 2031. Europe market for MHC-Peptide ... Read More
-
Cervical Cancer Treatment
... at a CAGR of 6.0% over the analysis period 2024-2030. Squamous Cell Carcinoma (SCC), one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$9.1 Billion by the ... Read More
-
Head and Neck Cancer Therapeutics
... Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. PD Inhibitors, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$2.5 Billion ... Read More
-
Cancer Insurance
... CAGR of 9.8% over the analysis period 2024-2030. Individual Plan, one of the segments analyzed in the report, is expected to record a 11.3% CAGR and reach US$87.1 Billion by the end of the analysis ... Read More
-
Nasopharyngeal Cancer Treatment
... at a CAGR of 6.2% over the analysis period 2024-2030. Radiation Therapy, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$289.8 Million by the end of ... Read More
-
Non-Muscle Invasive Bladder Cancer
... 2030, growing at a CAGR of 19.5% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 18.9% CAGR and reach US$4.5 Billion by the end ... Read More
-
Cancer Antibody Drug Conjugates
... 2030, growing at a CAGR of 15.0% over the analysis period 2024-2030. Kadcyla, one of the segments analyzed in the report, is expected to record a 17.6% CAGR and reach US$5.7 Billion by the end ... Read More
-
Neoantigen Cancer Vaccines
... at a CAGR of 20.3% over the analysis period 2024-2030. Personalized Neo-Antigen Vaccine, one of the segments analyzed in the report, is expected to record a 22.3% CAGR and reach US$52.5 Million by the end ... Read More
-
Pituitary Cancer
... CAGR of 8.9% over the analysis period 2024-2030. Pituitary Adenoma, one of the segments analyzed in the report, is expected to record a 10.1% CAGR and reach US$485.1 Million by the end of the analysis ... Read More
-
Anaplastic Thyroid Cancer Drugs
... 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$912.1 Million by the end ... Read More
-
Checkpoint Inhibitor Refractory Cancer
... 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. PD-1 Inhibitor Type, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$33.0 Billion by ... Read More
-
Head and Neck Cancer Diagnostics
... Billion by 2030, growing at a CAGR of 12.0% over the analysis period 2024-2030. Biopsy & Blood Tests, one of the segments analyzed in the report, is expected to record a 12.9% CAGR and reach ... Read More
-
Testicular Cancer Drugs
... at a CAGR of 2.7% over the analysis period 2024-2030. Seminoma Drugs, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$356.0 Million by the end of ... Read More
-
HER2 - Negative Breast Cancer
... Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Radiation, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$8.9 Billion by ... Read More
-
Cancer Biological Therapy
... at a CAGR of 6.0% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$69.9 Billion by the end of ... Read More
-
Hairy Cell Leukemia
... at a CAGR of 3.7% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$148.8 Billion by the end of the ... Read More
-
Bladder Cancer Detective Kits
... 2030, growing at a CAGR of 11.3% over the analysis period 2024-2030. Fluorescence In Situ Hybridization, one of the segments analyzed in the report, is expected to record a 12.9% CAGR and reach US$235.7 Million ... Read More
-
Personalized Cancer Medicines
... at a CAGR of 10.6% over the analysis period 2024-2030. Personalized Medicine Diagnostics, one of the segments analyzed in the report, is expected to record a 12.2% CAGR and reach US$258.0 Billion by the end ... Read More
-
Non-Invasive Cancer Diagnostics
... at a CAGR of 6.2% over the analysis period 2024-2030. Immunochemistry, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$100.5 Billion by the end of the ... Read More
-
Ovarian Cancer Drugs
... at a CAGR of 4.5% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$2.9 Billion by the end of ... Read More
-
Bile Duct Cancer
... at a CAGR of 5.7% over the analysis period 2024-2030. Surgical Therapy, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$154.1 Million by the end of ... Read More
Research Assistance
